HCC366 Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | HCC366 is a human lung adenosquamous carcinoma cell line established from the malignant pleural effusion of an 80-year-old European female patient at the Hamon Cancer Center, UT Southwestern Medical Center. Adenosquamous carcinoma is a rare mixed histological subtype of non-small cell lung cancer (NSCLC) combining features of both adenocarcinoma and squamous cell carcinoma. HCC366 is registered in Cellosaurus as CVCL_2059 and is included in the Cancer Dependency Map (DepMap), CCLE, COSMIC cell lines, and MD Anderson Cell Lines Project panels. The line carries a homozygous TP53 p.Tyr220Cys mutation (a structural mutation of the DNA-binding domain) and a heterozygous ATM p.Pro534Ala mutation. It does not carry KRAS, EGFR, or STK11 driver mutations, and exhibits microsatellite stability (MSS). The doubling time is approximately 60–70 hours. HCC366 is applicable in NSCLC research, particularly in studies of lung adenosquamous carcinoma biology, which remains understudied relative to pure adenocarcinoma or squamous cell carcinoma subtypes. Key applications include: TP53 gain-of-function mutation studies; ATM-mediated DNA damage response; chemotherapy sensitivity and resistance testing (cisplatin, paclitaxel, gemcitabine); evaluation of targeted agents; drug sensitivity profiling within DepMap and CCLE frameworks; biomarker discovery for mixed histology NSCLC; comparative genomics; and proteomic/transcriptomic profiling. HCC366 has also contributed to studies of lung cancer cell biology including proliferation, migration, and invasion mechanisms relevant to malignant pleural disease. HCC366 is maintained as an adherent monolayer culture in RPMI 1640 supplemented with 10% heat-inactivated FBS at 37°C in a humidified 5% CO₂ atmosphere. Cells are subcultured using Accutase at 80–90% confluency (split ratio 1:3 to 1:5, seeding density 1–3 × 10⁴ cells/cm²). Medium is renewed every 2–3 days. The line is registered with DSMZ as ACC-492 and is available through Cytion (catalog #302155). |
|---|---|
| Organism | Human |
| Tissue | Lung |
| Disease | Non-small cell lung cancer |
| Metastatic site | Malignant pleural effusion (site of sample collection) |
| Applications | NSCLC research; lung adenosquamous carcinoma biology; TP53 p.Tyr220Cys gain-of-function studies; ATM DNA damage response; chemotherapy sensitivity (cisplatin, paclitaxel, gemcitabine); DepMap/CCLE drug sensitivity profiling; biomarker discovery; NSCLC comparative genomics; malignant pleural disease biology |
| Synonyms | HCC-366, HCC0366, Hamon Cancer Center 366 |
Characteristics
| Age | 80 years |
|---|---|
| Gender | Female |
| Ethnicity | European |
| Morphology | Epithelial-like |
| Cell type | Epithelial cells |
| Growth properties | Monolayer, adherent |
Regulatory Data
| Citation | HCC366 (Cytion catalog number 302155) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_2059 |
| GMO Status | No genetic modification; wildtype NSCLC cell line with endogenous somatic mutations (TP53 p.Tyr220Cys homozygous; ATM p.Pro534Ala heterozygous) |
Biomolecular Data
| MSI-status | MSS |
|---|---|
| Mutational profile | TP53 p.Tyr220Cys (c.659A>G) Homozygous; ATM p.Pro534Ala (c.1600C>G) Heterozygous |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% heat-inactivated FBS |
| Dissociation Reagent | Accutase |
| Doubling time | approx. 60 to 70 hours |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Split ratio | 1 to 5 |
| Seeding density | 1 to 3 × 10⁴ cells/cm² |
| Fluid renewal | 2 to 3 times per week |
| Post-Thaw Recovery | After thawing, plate the cells at 5 × 10⁴ cells/cm² and allow at least 24 hours for adherence before the first medium change. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 302155-071024 | Certificate of Analysis | 23. May. 2025 | 302155 |